Behavior and Social Issues

, Volume 16, Issue 2, pp 197–213 | Cite as

Psychiatry’s Thirty-Five-Year, Non-Empirical Reach For Biological Explanations

  • W. Joseph WyattEmail author
  • Donna M. Midkiff


This is our third article in a series that began with a special issue of Behavior and Social Issues in 2006. Here we briefly review our central points from the first two articles. First is that over the past thirty-five years, claims of biological causation of mental and behavioral disorders have gone well beyond the research data, for reasons that are largely related to psychiatry’s lost esteem and protection of its “turf,” as well as to the financial interests of the pharmaceutical industry. Our second position is that claims of psychotropic drugs’ effectiveness have been overstated. We respond, as well, to the protestations of Professor Jerome C. Wakefield who defends biological psychiatry. We also provide an update on relevant events within the drug industry since our last article in this series.


FDA behaviorism biological causation pharmaceutical industry organized psychiatry efficacy of psychotropic medications identical twin studies brain imaging studies psychological paradigms 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Avorn, J. (2007). Paying for drug approvals—Who’s using whom? New England Journal of Medicine, 356, 1697–1700.
  2. Barlow, D. H. & Durand, V. M. (2005). Abnormal psychology: An integrative approach (4th Ed.). Belmont, CA: Thompson-Wadsworth.Google Scholar
  3. Berenson, A. (2006, December 17). Eli Lilly said to play down risk of top pill. The New York Times. Retrieved December 18, 2006, from
  4. Bouchard, T. J. & McGue, M. (2003). Genetic and environmental influences on human psychological differences. Retrieved June 21, 2007, from
  5. Campbell, E. G., Gruen, R. L., Mountford, J., Miller, L. G., Cleary, P. D., & Blumenthal, M. D. (2007). A national survey of physician-industry relationships. New England Journal of Medicine, 356, 1742–1750. Scholar
  6. Caruso, D. B. (2006, November 3). Med students taught to resist drug pitches. The Charleston Gazette, p. 3A.Google Scholar
  7. Comer, R. J. (2007). Abnormal psychology (6th Ed.). New York: Worth.Google Scholar
  8. Ex-FDA chief faces fine but no jail time. (2007, January 20). The Charleston Gazette, p. 6A.Google Scholar
  9. Ismail, M. A., & Bengtsson, H. (2007, April 1). Spending on lobbying thrives: Drug and health products industries invest $182 million to influence legislation. Center for Public Integrity Report. Retrieved April 13, 2007, from
  10. Kirsch, I., Moore, T. J., Scoboria, A. & Nicholls. (2002). The emperor’s new drugs: An analysis of antidepressant medication data submitted to the U.S. food and Drug Administration. Prevention & Treatment, 5, Article 23. Retrieved July 26, 2004 from Scholar
  11. Kravitz, R. L., Epstein, R. M., Feldman, M. D., Franz, C. E., Azari, R., Wilks, M. S., Hinton, L. & Franks, P. (2005). Influence of patients’ requests for direct-to-consumer antidepressants. Journal of the American Medical Association, 293, 1995–2002.CrossRefGoogle Scholar
  12. Leiberman, J. A., Stroup, T. S., McEvoy, J., Swartz, M., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J. & Hsiao, J. K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209–1223.CrossRefGoogle Scholar
  13. Mattaini, M. A. (Ed.). (2006). Mental illness, mental health, and cultural analytic science (Special issue). Behavior and social Issues, 15(2).
  14. MindFreedom (2003, July 28, August 12, 22, September, 26). Fast for freedom in mental health. Retrieved December 22, 2003, from
  15. Patient medication guides. (2007). Retrieved from on February 26, 2007.Google Scholar
  16. Pincock, S. (2006). Journal editor quits in conflict scandal. The Scientist. Retrieved August 30, 2006, from
  17. Plomin, R., Defries, J. C., Craig, I. W. & McGuffin, P. (Eds.). (2003). Behavioral genetics in the postgenomic era. Washington, DC: American Psychological Association.Google Scholar
  18. Skinner, B. F. (1974). About behaviorism. New York: Alfred A. Knopf.Google Scholar
  19. U. S. drug agency asks antidepressant makers to warn young adults of suicide risks. (2007). Associated Press. Retrieved May 2, 2007, from,2933,269643,00.html.
  20. Wakefield, J. C. (2006). Is behaviorism becoming a pseudo-science?: Power versus scientific rationality in the eclipse of token economies by biological psychiatry in the treatment of schizophrenia. Behavior and Social Issues, 15, 202–221. Scholar
  21. Wakefield, J. C. (2007). Is behaviorism becoming a pseudoscience?: Replies to Drs. Waytt, Midkiff and Wong. Behavior and Social Issues, 16, 170–189. Scholar
  22. Wong, S. E. (2006a). Behavior analysis of psychotic disorders: Scientific dead end or casualty of the mental health political economy? Behavior and Social Issues, 15, 152–177.
  23. Wong, S. E. (2006b). Response to the commentaries on: “Behavior analysis of psychotic disorders: Scientific dead end or casualty of the mental health political economy? Behavior and Social Issues, 15, 232–243.
  24. Wyatt, W. J. & Midkiff, D. M. (2006a). Biological psychiatry: A practice in search of a science. Behavior and Social Issues, 15, 132–151.
  25. Wyatt, W. J. & Midkiff, D. M. (2006b). Six-to-one gets the job done: Comments on the reviews. Behavior and Social Issues, 15, 222–231.

Copyright information

© W. Joseph Wyatt & Donna M. Midkiff 2007

Authors and Affiliations

  1. 1.Department of PsychologyMarshall UniversityHuntingtonUSA
  2. 2.Department of PsychologyRiver Park HospitalHuntingtonUSA

Personalised recommendations